• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于β-地中海贫血的基因组编辑:进展与挑战

Genome Editing for β-Hemoglobinopathies: Advances and Challenges.

作者信息

Frati Giacomo, Miccio Annarita

机构信息

Laboratory of Chromatin and Gene Regulation during Development, Imagine Institute, Université de Paris, INSERM UMR 1163, F-75015 Paris, France.

出版信息

J Clin Med. 2021 Jan 28;10(3):482. doi: 10.3390/jcm10030482.

DOI:10.3390/jcm10030482
PMID:33525591
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7865242/
Abstract

β-hemoglobinopathies are the most common genetic disorders worldwide and are caused by mutations affecting the production or the structure of adult hemoglobin. Patients affected by these diseases suffer from anemia, impaired oxygen delivery to tissues, and multi-organ damage. In the absence of a compatible donor for allogeneic bone marrow transplantation, the lifelong therapeutic options are symptomatic care, red blood cell transfusions and pharmacological treatments. The last decades of research established lentiviral-mediated gene therapy as an efficacious therapeutic strategy. However, this approach is highly expensive and associated with a variable outcome depending on the effectiveness of the viral vector and the quality of the cell product. In the last years, genome editing emerged as a valuable tool for the development of curative strategies for β-hemoglobinopathies. Moreover, due to the wide range of its applications, genome editing has been extensively used to study regulatory mechanisms underlying globin gene regulation allowing the identification of novel genetic and pharmacological targets. In this work, we review the current advances and challenges of genome editing approaches to β-hemoglobinopathies. Special focus has been directed towards strategies aimed at correcting the defective β-globin gene or at inducing fetal hemoglobin (HbF), which are in an advanced state of clinical development.

摘要

β-珠蛋白生成障碍性贫血是全球最常见的遗传性疾病,由影响成人血红蛋白产生或结构的突变引起。受这些疾病影响的患者患有贫血、组织氧输送受损和多器官损伤。在缺乏同种异体骨髓移植的合适供体时,终身治疗选择是对症治疗、红细胞输血和药物治疗。过去几十年的研究确立了慢病毒介导的基因治疗作为一种有效的治疗策略。然而,这种方法成本高昂,且根据病毒载体的有效性和细胞产品的质量,其结果存在差异。近年来,基因组编辑成为开发β-珠蛋白生成障碍性贫血治愈策略的一种有价值的工具。此外,由于其应用范围广泛,基因组编辑已被广泛用于研究珠蛋白基因调控的潜在机制,从而能够识别新的遗传和药物靶点。在这项工作中,我们回顾了基因组编辑方法治疗β-珠蛋白生成障碍性贫血的当前进展和挑战。特别关注了旨在纠正缺陷β-珠蛋白基因或诱导胎儿血红蛋白(HbF)的策略,这些策略正处于临床开发的 advanced state。(这里“advanced state”直译为“先进状态”,结合语境可能是“进展阶段”之类更合适的表述,但按要求不能添加解释,所以保留原文)

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/231c/7865242/6cab720c9901/jcm-10-00482-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/231c/7865242/4150a119149d/jcm-10-00482-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/231c/7865242/6cab720c9901/jcm-10-00482-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/231c/7865242/4150a119149d/jcm-10-00482-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/231c/7865242/6cab720c9901/jcm-10-00482-g002.jpg

相似文献

1
Genome Editing for β-Hemoglobinopathies: Advances and Challenges.用于β-地中海贫血的基因组编辑:进展与挑战
J Clin Med. 2021 Jan 28;10(3):482. doi: 10.3390/jcm10030482.
2
Genome editing approaches to β-hemoglobinopathies.基因组编辑治疗β-地中海贫血症。
Prog Mol Biol Transl Sci. 2021;182:153-183. doi: 10.1016/bs.pmbts.2021.01.025. Epub 2021 Mar 1.
3
Recent advance on genome editing for therapy of β-hemoglobinopathies.用于β-珠蛋白生成障碍性贫血治疗的基因组编辑最新进展。
Yi Chuan. 2018 Feb 20;40(2):95-103. doi: 10.16288/j.yczz.17-215.
4
Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.慢病毒和基因组编辑策略治疗β-血红蛋白病。
Blood. 2019 Oct 10;134(15):1203-1213. doi: 10.1182/blood.2019000949.
5
Comparative analysis of lentiviral gene transfer approaches designed to promote fetal hemoglobin production for the treatment of β-hemoglobinopathies.比较分析旨在促进胎儿血红蛋白产生以治疗β-血红蛋白病的慢病毒基因转移方法。
Blood Cells Mol Dis. 2020 Sep;84:102456. doi: 10.1016/j.bcmd.2020.102456. Epub 2020 May 29.
6
A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies.开启沉重之门的小钥匙:用于治疗血红蛋白病的基因疗法
Front Genome Ed. 2021 Feb 4;2:617780. doi: 10.3389/fgeed.2020.617780. eCollection 2020.
7
Treating hemoglobinopathies using gene-correction approaches: promises and challenges.使用基因校正方法治疗血红蛋白病:前景与挑战。
Hum Genet. 2016 Sep;135(9):993-1010. doi: 10.1007/s00439-016-1696-0. Epub 2016 Jun 17.
8
A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.一种治疗β-珠蛋白生成障碍性贫血的基因组编辑策略,该策略重现了与一种良性遗传疾病相关的突变。
Nat Med. 2016 Sep;22(9):987-90. doi: 10.1038/nm.4170. Epub 2016 Aug 15.
9
Clinical genome editing to treat sickle cell disease-A brief update.用于治疗镰状细胞病的临床基因组编辑——简要更新
Front Med (Lausanne). 2023 Jan 9;9:1065377. doi: 10.3389/fmed.2022.1065377. eCollection 2022.
10
Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges.β-地中海贫血症的基因治疗:里程碑、新疗法和挑战。
Mol Diagn Ther. 2019 Apr;23(2):173-186. doi: 10.1007/s40291-019-00383-4.

引用本文的文献

1
Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects.将CRISPR基因组编辑推进到基因治疗临床试验:进展与未来前景
Expert Rev Mol Med. 2025 Mar 31;27:e16. doi: 10.1017/erm.2025.10.
2
Genetic Polymorphisms Associated with Fetal Hemoglobin (HbF) Levels and F-Cell Numbers: A Systematic Review of Genome-Wide Association Studies.与胎儿血红蛋白 (HbF) 水平和 F 细胞数量相关的遗传多态性:全基因组关联研究的系统评价。
Int J Mol Sci. 2024 Oct 23;25(21):11408. doi: 10.3390/ijms252111408.
3
Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34 cell therapy to induce fetal hemoglobin for sickle cell disease.

本文引用的文献

1
High-level correction of the sickle mutation is amplified during erythroid differentiation.镰状突变的高水平校正会在红细胞分化过程中被放大。
iScience. 2022 May 10;25(6):104374. doi: 10.1016/j.isci.2022.104374. eCollection 2022 Jun 17.
2
Base and Prime Editing Technologies for Blood Disorders.用于血液疾病的碱基编辑和引导编辑技术。
Front Genome Ed. 2021 Jan 28;3:618406. doi: 10.3389/fgeed.2021.618406. eCollection 2021.
3
Gene Editing and Genotoxicity: Targeting the Off-Targets.基因编辑与基因毒性:靶向脱靶效应
新型 Cas9 基因编辑自体 CD34 细胞疗法诱导镰状细胞病胎儿血红蛋白的开发和 IND 支持研究。
Mol Ther. 2024 Oct 2;32(10):3433-3452. doi: 10.1016/j.ymthe.2024.07.022. Epub 2024 Jul 31.
4
Safety and efficacy studies of CRISPR-Cas9 treatment of sickle cell disease highlights disease-specific responses.CRISPR-Cas9治疗镰状细胞病的安全性和有效性研究突出了疾病特异性反应。
Mol Ther. 2024 Dec 4;32(12):4337-4352. doi: 10.1016/j.ymthe.2024.07.015. Epub 2024 Jul 22.
5
CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments.基于 CRISPR 的基因治疗:从临床前治疗到临床治疗。
Cells. 2024 May 8;13(10):800. doi: 10.3390/cells13100800.
6
β-Thalassemia gene editing therapy: Advancements and difficulties.β-地中海贫血基因编辑疗法:进展与困难
Medicine (Baltimore). 2024 May 3;103(18):e38036. doi: 10.1097/MD.0000000000038036.
7
CRISPR Advancements for Human Health.CRISPR 技术在人类健康领域的应用进展。
Mo Med. 2024 Mar-Apr;121(2):170-176.
8
Exagamglogene Autotemcel: First Approval.Exagamglogene Autotemcel:首次获批。
Mol Diagn Ther. 2024 Mar;28(2):133-139. doi: 10.1007/s40291-024-00696-z. Epub 2024 Jan 17.
9
Genome editing for sickle cell disease: still time to correct?镰状细胞病的基因组编辑:还有时间进行纠正吗?
Front Pediatr. 2023 Nov 2;11:1249275. doi: 10.3389/fped.2023.1249275. eCollection 2023.
10
Clinical and haematological characteristics of 38 individuals with Hb G-Makassar in Malaysia.马来西亚38例血红蛋白G-望加锡病患者的临床和血液学特征
EJHaem. 2023 Aug 10;4(4):940-948. doi: 10.1002/jha2.750. eCollection 2023 Nov.
Front Genome Ed. 2020 Dec 10;2:613252. doi: 10.3389/fgeed.2020.613252. eCollection 2020.
4
Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing.染色体重排是 CRISPR-Cas9 基因组编辑的一种靶向后果。
Nat Genet. 2021 Jun;53(6):895-905. doi: 10.1038/s41588-021-00838-7. Epub 2021 Apr 12.
5
Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq.通过 CAST-Seq 对基因编辑人类干细胞中的染色体重排进行定量评估。
Cell Stem Cell. 2021 Jun 3;28(6):1136-1147.e5. doi: 10.1016/j.stem.2021.02.002. Epub 2021 Feb 23.
6
Evaluation of Homology-Independent CRISPR-Cas9 Off-Target Assessment Methods.同源非依赖的 CRISPR-Cas9 脱靶评估方法的评估。
CRISPR J. 2020 Dec;3(6):440-453. doi: 10.1089/crispr.2020.0053.
7
ZNF410 Uniquely Activates the NuRD Component CHD4 to Silence Fetal Hemoglobin Expression.锌指蛋白 410(ZNF410)特异性激活 NuRD 组件 CHD4 以沉默胎儿血红蛋白表达。
Mol Cell. 2021 Jan 21;81(2):239-254.e8. doi: 10.1016/j.molcel.2020.11.006. Epub 2020 Dec 9.
8
Tools for experimental and computational analyses of off-target editing by programmable nucleases.可编程核酸酶脱靶编辑的实验和计算分析工具。
Nat Protoc. 2021 Jan;16(1):10-26. doi: 10.1038/s41596-020-00431-y. Epub 2020 Dec 7.
9
Post-Transcriptional Genetic Silencing of to Treat Sickle Cell Disease.用 治疗镰状细胞病的转录后基因沉默。
N Engl J Med. 2021 Jan 21;384(3):205-215. doi: 10.1056/NEJMoa2029392. Epub 2020 Dec 5.
10
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.CRISPR-Cas9 基因编辑治疗镰状细胞病和 β-地中海贫血。
N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5.